logo
Here's how a bio implant stopped Long Island woman's ‘horrific' athritis in its tracks: ‘This is the future'

Here's how a bio implant stopped Long Island woman's ‘horrific' athritis in its tracks: ‘This is the future'

New York Post14-05-2025
A Long Island speech pathologist said a pioneering bio implant stopped her 'horrific' rheumatoid arthritis in its tracks.
Massapequa's Dawn Steiner, 58, said even a simple handshake would mean agony — and after 15 years she retreated into a reclusive lifestyle.
'My husband had to help me get dressed,' she told The Post.
Advertisement
3 Massapequa speech pathologist Dawn Steiner, 58, said a bio implant stopped her 'horrific' rheumatoid arthritis.
Northwell Health
'I could not wash my hair. I could barely take a shower by myself.'
But her new state-of-the-art bio-implant has miraculously regulated the RA with minimal invasiveness — and just a minute of daily stimulation. It is linked to Steiner's vagus nerve, a crucial connector between the brain, major organs, and other bodily functions.
Advertisement
'We discovered a reflex that slows down inflammation by sending signals to the immune system through the vagus nerve,' said Dr. Kevin Tracey, president and CEO of Northwell's Feinstein Institutes for Medical Research on Long Island.
'The vagus nerve carries the signals that turn off inflammation … It's like pushing on the brakes of your car.'
The company he co-founded, SetPoint Medical, designed the smaller-than-a-quarter bio-implant 'sitting' atop the vagus nerve in the front of Steiner's neck with hardly a scar to show.
'My pain was at a seven or an eight out of ten, now it's at a one,' Steiner said of the life-changing device that uses AI techn and has been functioning for about a year.
Advertisement
'I really believe that this is the future.'
3 Steiner received a state-of-the-art bio-implant that has miraculously regulated the condition with minimal invasiveness — and just a minute of daily stimulation.
Dennis A. Clark/NY Post
Touching a nerve
The still-to-be FDA-approved approach began in a 2023 medical trial of 242 Americans that Steiner was open to because she believed she was out of other options.
'We're huge Mets fans and there were seasons I couldn't go to a single game,' she said.
Advertisement
'I would come home from work and get right into bed. The whole weekend was spent in bed, or on the couch sleeping.'
Before the implant, doctors started Steiner on methotrexate, 'which is a like a low-dose chemo,' she said.
That led to trying eight different biologic medications that would take hours to infuse — plus 'the side effects can be cancer and death,' said Steiner.
She experienced her entire face and other parts of her body go numb to the point that medical professionals tested her for multiple sclerosis.
'They would tell me it takes up to six months for it to kick in,' she said.
'All that time you're in horrific pain, and switching off took another few months.'
Last year, after being involved in the trial, Steiner reached a breaking point and opted to have the surgery that took only an hour by Northwell's Dr. Ashesh Mehta.
Advertisement
3
Northwell Health
'The unknowns weren't anything more unsettling than the medications I was already on.'
'Pioneering advance'
Tracey explained that the high-tech device works with an antenna connecting to a doctor's tablet for two-way readings and modifications every six weeks. The implant itself needs to be swapped out every ten years.
'This will be a highly significant advance, a pioneering advance, as a new way to give therapy to people who seriously need it,' said Tracey, who just published a book on the vagus nerve titled 'The Great Nerve.'
Advertisement
Steiner said she only feels an occasional buzz like a cell phone from the device during its daily minute of activity — she has it timed for 5 a.m. as a biological alarm clock — and hardly knows it is there otherwise.
It's charged through a band that is lighter than a bar of soap, which Steiner wears for only 30 minutes weekly.
'I have it around my neck on Sunday mornings while I'm doing the dishes and other housework,' she said.
Advertisement
Now, Steiner is back at Citi Field rooting on her Mets, going to see her favorite band, The Foo Fighters, and going for walks on the beaches of the island.
Seeing its early success, Tracey is optimistic that the FDA will move quickly to green light the implant for broader use.
'This could be as soon as the summer,' he said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Boston Scientific Stock Outlook: Is Wall Street Bullish or Bearish?
Boston Scientific Stock Outlook: Is Wall Street Bullish or Bearish?

Yahoo

time2 hours ago

  • Yahoo

Boston Scientific Stock Outlook: Is Wall Street Bullish or Bearish?

Boston Scientific Corporation (BSX), headquartered in Marlborough, Massachusetts, develops, manufactures, and markets medical devices for use in various interventional medical specialties globally. With a market cap of $157.9 billion, the company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, and more. Shares of this medTech giant have outperformed the broader market over the past year. BSX has gained 41.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 16.6%. In 2025, BSX stock is up 17.5%, surpassing the SPX's 7.8% rise on a YTD basis. More News from Barchart With UnitedHealth Under DOJ Investigation, Should You Buy, Sell, or Hold UNH Stock Now? Trump Won't Take Away Tesla's Subsidies. Does That Make TSLA Stock a Safe Buy Here? Can AMD Stock Hit $210 in 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Zooming in further, BSX's outperformance is also apparent compared to the iShares U.S. Medical Devices ETF (IHI). The exchange-traded fund has gained about 9% over the past year. Moreover, BSX's double-digit gains on a YTD basis outshine the ETF's 2.3% gains over the same time frame. BSX's strong performance can be credited to its robust product portfolio and dedicated global team. Key achievements in the second quarter include FDA approval for expanding the FARAPULSE PFA System, initiation of the ReMATCH IDE trial, and securing CE Mark for the WATCHMAN FLX Pro device in Europe. The company also finalized the acquisitions of Intera Oncology and SoniVie, enhancing its offerings in liver cancer and hypertension treatment technologies. On Jul. 23, BSX shares closed up more than 4% after reporting its Q2 results. Its adjusted EPS of $0.75 beat Wall Street's expectations of $0.72. The company's revenue was $5.1 billion, exceeding Wall Street forecasts of $4.9 billion. The company expects full-year adjusted EPS in the range of $2.95 to $2.99. For the current fiscal year, ending in December, analysts expect BSX's EPS to grow 18.7% to $2.98 on a diluted basis. The company's earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters. Among the 30 analysts covering BSX stock, the consensus is a 'Strong Buy.' That's based on 27 'Strong Buy' ratings, two 'Moderate Buys,' and one 'Hold.' This configuration is more bullish than two months ago, with 26 analysts suggesting a 'Strong Buy.' On Jul. 24, Raymond James Financial, Inc. (RJF) analyst Jayson Bedford maintained a 'Buy' rating on BSX with a price target of $124, implying a potential upside of 18.2% from current levels. The mean price target of $124.53 represents an 18.7% premium to BSX's current price levels. The Street-high price target of $140 suggests an ambitious upside potential of 33.4%. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on

BofA Securities Affirms ‘Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects
BofA Securities Affirms ‘Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects

Yahoo

time4 hours ago

  • Yahoo

BofA Securities Affirms ‘Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is . On July 11, BofA Securities initiated coverage of the stock with a 'Buy' rating and an $8 price target. The positive stance comes as the research firm remains buoyed by the company's Taysha gene therapy TSHA-102 under development for Rett Syndrome. Copyright: dolgachov / 123RF Stock Photo The research firm believes TSHA-102 has the potential to become the first approved disease-modifying treatment for the severe neurodevelopmental disease. Clinical trials have already demonstrated that the therapy has the potential to help patients regain or achieve developmental milestones. Taysha Gene Therapies has already reached an alignment with the US Food and Drug Administration on a pivotal trial design for TSHA-102. The company plans to initiate a trial in the third quarter of 2023. BofA Securities views the candidate treatment as a commercially attractive opportunity. Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a clinical-stage biotech company focused on developing and bringing to market gene therapies for serious monogenic disorders affecting the central nervous system. It seeks to address unmet medical needs by developing transformative medicines for these diseases. Its approach centers on using adeno-associated virus (AAV)-based gene therapies. While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Video/Pic: Trump demands drug companies lower prices
Video/Pic: Trump demands drug companies lower prices

American Military News

time5 hours ago

  • American Military News

Video/Pic: Trump demands drug companies lower prices

President Donald Trump sent 17 pharmaceutical companies letters on Thursday and demanded that the companies lower prices for Americans. The president warned that the 'unacceptable burden' of prescription drug prices will 'end' with his administration. During a press briefing on Thursday, White House Press Secretary Karoline Leavitt said, 'The president signed an executive order earlier this year to solve the problem of exorbitant pharmaceutical pricing.' 'According to recent data, the prices that Americans have been paying for brand-name drugs are more than three times the price other similarly developed nations pay,' Leavitt added. 'The president is determined to solve this problem and took further action today. He has signed 17 letters to pharmaceutical companies' CEOs.' .@PressSec reads one of the letters sent by @POTUS today to the CEOs of pharmaceutical companies: "Moving forward, the only thing I will accept from drug manufacturers is a commitment that provides American families immediate relief from the vastly inflated drug prices…" — Rapid Response 47 (@RapidResponse47) July 31, 2025 Leavitt also shared the letter Trump wrote to the CEO of Eli Lilly and Company. In the letter, Trump warned Eli Lilly and 16 other pharmaceutical companies that the 'unacceptable burden' of brand-name drugs costing 'up to three times higher on average' for Americans than for citizens of other countries 'ends with my administration.' Trump told the pharmaceutical companies, 'Most proposals the Trump administration has received to resolve this critical issue promised more of the same shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry.' The president added, 'Moving forward, the only thing I will accept from drug manufacturers is a commitment that provides American families immediate relief from the vastly inflated drug prices and an end to the free ride of American innovation by European and other developed nations.' READ MORE: Video: Trump order against 'Big Pharma' aims to reduce drug prices While Trump explained that a collaborative effort to reach 'global pricing parity' would be most effective for pharmaceutical companies, the U.S. government, and U.S. patients, he warned that his administration will 'deploy every tool in our arsenal to protect American families' if pharmaceutical companies refuse to take action. In addition to the letter sent to Eli Lilly and Company, Trump sent letters to AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Genentech, Gilead Sciences, GSK, Johnson and Johnson, Merck, Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals, and Sanofi. In the letters, Trump gave the companies 60 days to extend 'Most-Favored-Nation' pricing to Medicaid and provide 'full portfolios' of drugs for Medicaid patients, guarantee Most-Favored-Nation pricing for new drugs, negotiate with 'foreign freeloading nations' and return 'increased revenues abroad' to patients in the United States, and allow Americans to directly purchase drugs at Most-Favored-Nation prices. Today, @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. If they refuse to step up, the Administration will use every tool to protect Americans from continued abusive drug pricing practices. Letter to Eli Lilly: — Rapid Response 47 (@RapidResponse47) July 31, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store